All In Biotech

Drug Trial Radar · NCT05401357

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Last checked: Nov 20, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jun 29, 2022

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Amneal Pharmaceuticals, LLCIndustry
Sponsor type
Industry
Collaborators
CBCC Global Research
First posted
Jun 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.

Conditions

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Interventions

  • Test - Bimatoprost 0.01% Ophthalmic SolutionDrug

    Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.

  • Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Drug

    Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups.Time frame: Day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation Inc.

    Newport Beach, California · Recruiting

  • North Bay Eye Associates, Inc.

    Petaluma, California · Recruiting

  • Volusia Eye Associates

    New Smyrna Beach, Florida · Recruiting

  • Clayton Eye Clinical Research, LLC

    Morrow, Georgia · Recruiting

  • Coastal Research Associates, LLC

    Roswell, Georgia · Recruiting

  • Toyos Clinic

    Nashville, Tennessee · Recruiting

  • Keystone Research

    Austin, Texas · Not yet recruiting

  • Houston Eye Associates, North Loop

    Houston, Texas · Recruiting

  • Cheyenne Eye Clinic & Surgery Center

    Cheyenne, Wyoming · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.